Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

380 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Di Leo A, Johnston S, Lee KS, Ciruelos E, Lønning PE, Janni W, O'Regan R, Mouret-Reynier MA, Kalev D, Egle D, Csőszi T, Bordonaro R, Decker T, Tjan-Heijnen VCG, Blau S, Schirone A, Weber D, El-Hashimy M, Dharan B, Sellami D, Bachelot T. Di Leo A, et al. Among authors: lonning pe. Lancet Oncol. 2018 Jan;19(1):87-100. doi: 10.1016/S1470-2045(17)30688-5. Epub 2017 Dec 7. Lancet Oncol. 2018. PMID: 29223745 Clinical Trial.
Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer.
Lønning PE, Geisler J, Krag LE, Erikstein B, Bremnes Y, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Paolini J, Polli A, Massimini G. Lønning PE, et al. J Clin Oncol. 2005 Aug 1;23(22):5126-37. doi: 10.1200/JCO.2005.07.097. Epub 2005 Jun 27. J Clin Oncol. 2005. PMID: 15983390 Clinical Trial.
Aromatase inhibitors as adjuvant treatment of breast cancer.
Geisler J, Lønning PE. Geisler J, et al. Among authors: lonning pe. Crit Rev Oncol Hematol. 2006 Jan;57(1):53-61. doi: 10.1016/j.critrevonc.2005.05.005. Epub 2005 Dec 7. Crit Rev Oncol Hematol. 2006. PMID: 16337805 Review.
Molecular basis for therapy resistance.
Lønning PE. Lønning PE. Mol Oncol. 2010 Jun;4(3):284-300. doi: 10.1016/j.molonc.2010.04.005. Epub 2010 Apr 24. Mol Oncol. 2010. PMID: 20466604 Free PMC article. Review.
Long-Term Follow-Up of the Intergroup Exemestane Study.
Morden JP, Alvarez I, Bertelli G, Coates AS, Coleman R, Fallowfield L, Jassem J, Jones S, Kilburn L, Lønning PE, Ortmann O, Snowdon C, van de Velde C, Andersen J, Del Mastro L, Dodwell D, Holmberg S, Nicholas H, Paridaens R, Bliss JM, Coombes RC. Morden JP, et al. Among authors: lonning pe. J Clin Oncol. 2017 Aug 1;35(22):2507-2514. doi: 10.1200/JCO.2016.70.5640. Epub 2017 May 3. J Clin Oncol. 2017. PMID: 28467729 Free PMC article. Clinical Trial.
380 results